HealthInvest Partners AB Increases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

HealthInvest Partners AB raised its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 18.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,840 shares of the biopharmaceutical company’s stock after buying an additional 51,368 shares during the quarter. Amicus Therapeutics comprises about 1.4% of HealthInvest Partners AB’s portfolio, making the stock its 22nd biggest holding. HealthInvest Partners AB’s holdings in Amicus Therapeutics were worth $3,076,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Wellington Management Group LLP grew its stake in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $259,000. Neo Ivy Capital Management purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $702,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Amicus Therapeutics by 51.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock valued at $2,381,000 after purchasing an additional 75,807 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Amicus Therapeutics by 10.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after buying an additional 242,672 shares in the last quarter.

Amicus Therapeutics Stock Up 1.3 %

Shares of NASDAQ FOLD opened at $9.19 on Monday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business’s 50 day moving average is $9.56 and its two-hundred day moving average is $10.42. Amicus Therapeutics, Inc. has a 52-week low of $8.78 and a 52-week high of $14.02. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -51.06, a PEG ratio of 1.51 and a beta of 0.61.

Analyst Upgrades and Downgrades

FOLD has been the subject of several analyst reports. Morgan Stanley restated an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday. Finally, JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.